

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM737018

SUBMISSION TYPE:	RESUBMISSION		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
RESUBMIT DOCUMENT ID:	900687500		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
U.S. Bank National Association		03/31/2022	National Banking Association: DELAWARE
RECEIVING PARTY DATA			
Name:	Origin Biosciences, Inc.		
Street Address:	75 Park Plaza		
City:	Boston		
State/Country:	MASSACHUSETTS		
Postal Code:	02116		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	6531804	NULIBRY	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	858-509-4071		
Email:	sdipdocket@pillsburylaw.com		
Correspondent Name:	Michelle L. Mehok		
Address Line 1:	11682 El Camino Real, Suite 200		
Address Line 4:	San Diego, CALIFORNIA 92130		
ATTORNEY DOCKET NUMBER:	074540-0000016		
NAME OF SUBMITTER:	Michelle L. Mehok		
SIGNATURE:	/michelle mehok/		
DATE SIGNED:	06/24/2022		
Total Attachments: 5			
source=BBio - IP Release (NULIBRY)#page1.tif			
source=BBio - IP Release (NULIBRY)#page2.tif			
source=BBio - IP Release (NULIBRY)#page3.tif			

source=BBio - IP Release (NULIBRY)#page4.tif

source=BBio - IP Release (NULIBRY)#page5.tif

INTELLECTUAL PROPERTY RELEASE AND REASSIGNMENT

THIS INTELLECTUAL PROPERTY RELEASE AND REASSIGNMENT (“Release”) is made as of March 31, 2022, by U.S. Bank National Association (“Agent”) as agent for itself and for the Lenders. Capitalized terms used but not defined herein shall have the same meanings assigned to such terms in the Security Agreement (as defined below).

WITNESSETH:

WHEREAS, BridgeBio Pharma, Inc., a Delaware corporation, Origin Biosciences, Inc., a Delaware corporation (“Grantor”), Eidos Therapeutics, Inc., a Delaware corporation, QED Therapeutics, Inc., a Delaware corporation, Adrenas Therapeutics, Inc., a Delaware corporation, and Phoenix Tissue Repair, Inc., a Delaware corporation and Agent are parties to that certain Intellectual Property Security Agreement dated as of November 17, 2021 (the “Security Agreement”) pursuant to which the Grantor granted a security interest to Agent for the ratable benefit of the Lenders in certain Intellectual Property Collateral as security for certain obligations owing by Grantor to Agent, including the Patents set forth on Schedule B thereto and the Trademarks set forth on Schedule C thereto and;

WHEREAS, the Security Agreement was recorded on November 17, 2021 by the Trademark Division of the United States Patent and Trademark Office at Reel 7497, Frame 0731 and by the Patent Division of the United States Patent and Trademark Office at Reel 058144, Frame 0302;

WHEREAS, Grantor has requested that Agent, for itself and on behalf of the Lenders, release all of its security interest in the Released Collateral (as defined below) and reassign any and all rights in the same to Grantor.

NOW THEREFORE, for good and valuable consideration, receipt and sufficiency of which are hereby acknowledged:

1. Agent, on behalf of itself and the Lenders, their successors, legal representatives and assigns, hereby terminates, releases and discharges any and all liens and security interests in Grantor’s Intellectual Property Collateral granted pursuant to the Security Agreement and any and all of Agent’s right, title, claim and interest that it may have in, to and under Grantor’s Intellectual Property Collateral pursuant to the Security Agreement and, more specifically, in, to and under the following (collectively, the “Released Collateral”):

- (i) each Trademark listed on Schedule A annexed hereto;
- (ii) each Patent listed on Schedule B annexed hereto; and
- (iii) all proceeds and products of any of the foregoing.

2. Agent hereby reassigns, grants and conveys to the Grantor, without any representation, recourse or undertaking by Agent, any and all of Agent’s right, title and interest in and to the Released Collateral.

3. Agent agrees, at the Grantor’s expense, to take all further actions, and provide to the Grantor and its successors, assigns and legal representatives all such cooperation and assistance, including, without limitation, the execution and delivery of any and all further documents or other instruments, as the Grantor and its successors, assigns and legal representatives may reasonably request in order to confirm, effectuate or record this Release.

4. This Release and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with the laws of the State of New York.

[Signature Page Follows]

IN WITNESS WHEREOF, Agent has caused this Intellectual Property Release and Reassignment to be executed as of the day and year first above written.

U.S. BANK NATIONAL ASSOCIATION, as
Collateral Agent

By: 
Name: Alison D.B. Nadeau
Title: Vice President

SCHEDULE A

Trademarks

Owner	Trademark	Application No. / Application Date	Registration No. / Issue Date	Status
Origin Biosciences, Inc.	NULIBRY	90/015,984 6/23/2020	6,531,804 10/19/2021	Registered

SCHEDULE B

Patents

Patent Ref.	Patent No.	Current Owner(s)	Jurisdiction	Issuance Date
Method for Obtaining Precursor Z and Use Thereof for the Production of a Means for Therapy of Human Molybdenum Cofactor Deficiency	7,504,095	Origin	US	17-Mar-2009
Method for Synthesizing Molybdopterin Precursor Z Derivatives	9,260,462	Origin	US	16-Feb-2016